The earnings call had a positive tone overall, with significant progress reported in the Australian oncology trial and promising preclinical data in long COVID. Financial management showed effective cost reduction and strategic refocusing, although some setbacks were noted with the discontinuation of the Indian trial and a patient death in the trial.

Company Guidance -

Q2 2026

In the recent Aethlon Medical fiscal first quarter 2026 earnings call, the company provided guidance highlighting several key metrics. The call revealed a significant reduction in operating expenses, down by 32% to $1.8 million compared to the previous year, primarily due to payroll-related savings and reduced legal fees. Aethlon also reported a cash balance of approximately $3.8 million as of June 30, 2025. Strategic focus was placed on the Australian oncology trial, with expectations to complete treatments by late 2025 or early 2026, facilitating a PMA or efficacy trial in Australia. This decision is projected to conserve $500,000 to $1 million by foregoing the previously planned Indian trial. The company also noted promising preclinical data, including a 98.5% removal rate of platelet-derived extracellular vesicles in simulated treatments, and is actively pursuing regulatory approval for the Hemopurifier across multiple diseases, including long COVID.

Progress in Australian Oncology Trial

The first cohort of the Australian oncology trial was completed with no adverse events. An independent Data Safety Monitoring Board recommended advancing to the second cohort of treatments. This indicates progress towards meeting the primary safety endpoint.

Preclinical Success in Long COVID

Presented preclinical data at the Keystone Symposium showing that the Hemopurifier can remove extracellular vesicles implicated in long COVID. This indicates potential for addressing a significant unmet medical need.

Operating Expense Reduction

Consolidated operating expenses reduced by 32% year-over-year from $2.6 million to $1.8 million, mainly due to payroll-related savings and lower legal fees.

Cash Preservation Strategy

Decision to not proceed with the Indian trial will conserve $500,000 to $1 million, focusing resources on Australian trial for faster progression.

Aethlon Medical (AEMD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AEMD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 18, 2025	2026 (Q2)	-0.51 / -	-1.6	―	―	―
Aug 13, 2025	2026 (Q1)	-0.86 / -0.85	-2.72	68.75% (+1.87)	―
Jun 26, 2025	2025 (Q4)	-1.07 / -3.22	-6.96	53.74% (+3.74)	―
Feb 12, 2025	2025 (Q3)	-1.63 / -1.04	-10.96	90.51% (+9.92)	―
Nov 13, 2024	2025 (Q2)	-1.56 / -1.60	-9.76	83.61% (+8.16)	―
Aug 14, 2024	2025 (Q1)	-2.52 / -2.72	-11.2	75.71% (+8.48)	―
Jun 27, 2024	2024 (Q4)	-9.84 / -6.96	-8	13.00% (+1.04)	―
Feb 14, 2024	2024 (Q3)	-10.80 / -10.96	-9.6	-14.17% (-1.36)	―
Nov 14, 2023	2024 (Q2)	-11.20 / -9.76	-14.4	32.22% (+4.64)	―
Aug 10, 2023	2024 (Q1)	-10.40 / -11.20	-15.2	26.32% (+4.00)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AEMD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 13, 2025	$1.23	$1.17	-4.88%
Jun 26, 2025	$1.94	$1.25	-35.57%
Feb 12, 2025	$5.34	$5.05	-5.43%
Nov 13, 2024	$3.25	$3.19	-1.85%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Aethlon Medical Inc (AEMD) report earnings?

Aethlon Medical Inc (AEMD) is schdueled to report earning on Nov 18, 2025, After Close (Confirmed).

What is Aethlon Medical Inc (AEMD) earnings time?

Aethlon Medical Inc (AEMD) earnings time is at Nov 18, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AEMD EPS forecast?

AEMD EPS forecast for the fiscal quarter 2026 (Q2) is -0.51.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing